Can Your Trial Payment Approach Stand Up To Regulatory Scrutiny?

Patient payments in clinical trials are often treated as a back-end operational task — but growing regulatory scrutiny is forcing sponsors to rethink that approach. Fragmented systems, manual reimbursements, and inconsistent documentation create significant compliance risks, particularly as regulators focus more closely on transparency, auditability, and ethical practices.

A compliant payment strategy must balance operational efficiency with core bioethical principles outlined in The Belmont Report: respect for persons, beneficence, and justice. This means avoiding undue financial influence, minimizing out-of-pocket burden for participants, and ensuring equitable access to trials. When payments are poorly managed, sponsors risk not only audit findings but also higher dropout rates and reduced diversity.

Centralizing payments and logistics into a single, traceable system enables stronger audit trails, consistent compensation practices, and a better patient experience. Evaluate how your current approach measures up—and identify where gaps could expose your trial to unnecessary risk.